Verge & Ferrer are collaborating to advance Verge’s ALS lead drug candidate, VRG50635, which is one of the first AI-discovered drugs in the clinic. The partnership underscores the CONVERGE® platform's value in identifying novel disease targets. bit.ly/3PA1ctA

At #BIOEuropeSpring , catch Verge's Jane Rhodes presentation on how our AI-enabled CONVERGE® platform aims to accelerate drug discovery and development. Learn more & register here: bit.ly/4a2KWJC #AI

On #InternationalWomensDay , we honor women worldwide who challenge norms to redefine the future of healthcare, including our CEO Alice Zhang and all the women at Verge who are at the forefront of innovation and pushing the boundaries of what's possible. #IWD2024

We're looking forward to the TRICALS Masterclass on Thursday, where Dr. Diego Cadavid will share his expertise on designing innovative ALS clinical trials. Learn more: bit.ly/49Ei1ev

#ALSResearch #innovation

Join us at the virtual Evercore ISI 2024 Emerging Biotech Conference on Feb 28, 10:45 AM E.T., as Verge Co-founder & CEO Alice Zhang presents insights into our innovative approach in drug discovery using #AI & human data: bit.ly/42LDaBa.
#biotechnology #investors

Biotech has long recognized the benefits of using digital endpoints in clinical trials. Putting it into practice has been another matter. Our CMO, Diego Cadavid, spoke to BioCentury Inc. about how Verge is paving the way with a digital-first approach in our proof-of-concept study

We’re thrilled to share the initiation of our proof-of-concept study for VRG50635 for the treatment of #ALS . By leveraging our AI-enabled CONVERGE® platform & patient data, we're enabled to more efficiently develop drugs for deadly diseases like ALS: bit.ly/3HbVNEp

Don't miss Verge's co-founder & CEO, Alice Zhang, at next week's 42nd Annual J.P. Morgan Healthcare Conference, where she will provide an update on Verge's progress in accelerating #drugdiscovery & development: bit.ly/47gXWJG

#JPM24 #JPM2024 #healthcare #AI

We're thrilled to unveil a partnership between Verge Genomics & Modality.AI! We aim to deliver more comprehensive insights into how VRG50635 may benefit people with ALS & help revolutionize how clinical trial studies collect crucial patient data: bit.ly/3GnpMsy

Verge is honored to be this year's California Life Sciences (CLS) Pantheon Award Winner for Emerging #Innovation . Victor Hanson-Smith shares how Verge's technical and cultural innovation has driven Verge’s success. bit.ly/3uc4rzv
#Pantheon2023

We’re honored to receive this year's California Life Sciences (CLS) award for Emerging Innovation. Watch our own Victor Hanson-Smith’s powerful remarks on how innovation is driven by our commitment to investing in a culture of radical candor. #Pantheon2023 #biotechnology

We're thrilled to announce a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium world-class researchers to use the power of our CONVERGE® platform to discover novel therapeutic approaches to #schizophrenia . Learn more: lnkd.in/gnjNpuCQ

At the #FierceBiotechSummit , our CMO Diego Cadavid shared his perspective on the role of #AI in drug discovery and development, and how Verge is streamlining the process through our AI-powered all-in-human CONVERGE® platform and human tissue data. Fierce Life Sciences Events

Don't miss Verge's CSO Robert Scannevin at the I Am Biotech Investor Forum, where he'll join other #biotech leaders in a panel discussion about the use of biomarkers in the clinical development of therapies for neurodegenerative diseases. #AI

How is #AI revolutionizing drug discovery and development? And what does a revolution really mean? At the #FierceBiotechSummit , our CMO, Diego Cadavid, will share his views on a topic that’s critical to the future of medicine.

We're looking forward to presenting at the annual NEALS Consortium meeting! We'll be sharing a poster from our Phase 1 trial for VRG50635, a potential treatment for #ALS and one of the first drugs entirely discovered from an AI-enabled platform to enter clinical trials. #NEALSMtg

We're thrilled to be a finalist for the Pantheon Awards! We were named a finalist in the Emerging #Innnovation category, which awards a company with the potential to transform the life sciences landscape. Please vote for us by Oct. 13! bit.ly/45dOohw #Pantheon2023

New episode from the Impact AI podcast! Listen to hear our Head of Computational Biology discuss how advances in #AI and #machinelearning have the potential to revolutionize #drugdiscovery and learn about Verge's all-in-human CONVERGE™ platform: bit.ly/46bNz9T

Verge's Chief Business Officer, Jane Rhodes, shares how biotech companies are increasingly using #AI to accelerate #drugdiscovery , and how large pharma is embracing this #innovation . Read her perspective and learn about our newest collaboration with Alexion.

We're at the American Neurological Association annual meeting today and sharing results from our Phase 1 clinical trial of VRG50635 - a potential treatment for #ALS & one of the first drugs discovered & developed from an #AI -powered platform. #innovation #ANA2023